Berry Genomics Co.,Ltd (SHE:000710)
China
· Delayed Price · Currency is CNY 14.47
-0.44 (-2.95%)
Jun 5, 2025, 2:45 PM CST
Berry Genomics Co.,Ltd Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -207.13 | -192.43 | -427.2 | -248.93 | -110.82 | 210.67 | Upgrade
|
| Depreciation & Amortization | 91.05 | 91.05 | 113.94 | 102.72 | 106.4 | 76.9 | Upgrade
|
| Other Amortization | 9.31 | 9.31 | 8.91 | 12.56 | 13.83 | 13.41 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1.74 | -1.74 | 0.01 | 0.35 | -0.26 | 0.45 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.66 | 0.66 | 159.38 | 0.07 | 5.16 | 0.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | 40.16 | 40.16 | 82.67 | 144.31 | 49.13 | -41.4 | Upgrade
|
| Provision & Write-off of Bad Debts | 130.68 | 130.68 | 162.77 | 98 | 53.6 | 31.6 | Upgrade
|
| Other Operating Activities | 42.17 | 19.35 | 21.47 | 5.54 | 31.98 | 23.54 | Upgrade
|
| Change in Accounts Receivable | -16.69 | -16.69 | 83.22 | -24.6 | -134.88 | -295.23 | Upgrade
|
| Change in Inventory | 31.95 | 31.95 | 0.89 | 6.85 | -57.53 | 20.28 | Upgrade
|
| Change in Accounts Payable | -30.3 | -30.3 | -38.2 | -88.03 | 152.02 | 105.93 | Upgrade
|
| Change in Other Net Operating Assets | 0.63 | 0.63 | -11.26 | 50.74 | 22.42 | 6.97 | Upgrade
|
| Operating Cash Flow | 96.1 | 87.97 | 111.01 | 21.18 | 94.03 | 161.31 | Upgrade
|
| Operating Cash Flow Growth | -12.49% | -20.75% | 424.14% | -77.48% | -41.71% | 31.09% | Upgrade
|
| Capital Expenditures | -61.5 | -56.75 | -55.1 | -73.31 | -336.69 | -112.55 | Upgrade
|
| Sale of Property, Plant & Equipment | 423.26 | 421.04 | 0.13 | 0.09 | 0.43 | 0.03 | Upgrade
|
| Divestitures | - | - | - | 1.71 | - | 190.39 | Upgrade
|
| Investment in Securities | -173.72 | -171.5 | 0.6 | 20.22 | -11.21 | -0.65 | Upgrade
|
| Other Investing Activities | -2.36 | -2.36 | 7 | 1.87 | - | 1.75 | Upgrade
|
| Investing Cash Flow | 185.68 | 190.43 | -47.37 | -49.42 | -347.47 | 78.97 | Upgrade
|
| Long-Term Debt Issued | - | 123.3 | 212.43 | 286.27 | 207.87 | 404.05 | Upgrade
|
| Total Debt Issued | 140 | 123.3 | 212.43 | 286.27 | 207.87 | 404.05 | Upgrade
|
| Long-Term Debt Repaid | - | -353.54 | -264.22 | -339.28 | -199.05 | -239.35 | Upgrade
|
| Total Debt Repaid | -320.8 | -353.54 | -264.22 | -339.28 | -199.05 | -239.35 | Upgrade
|
| Net Debt Issued (Repaid) | -180.8 | -230.24 | -51.79 | -53.01 | 8.82 | 164.71 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 56.46 | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -150.12 | Upgrade
|
| Common Dividends Paid | -6.61 | -8.69 | -15.5 | -28.29 | -9.59 | -29.21 | Upgrade
|
| Other Financing Activities | 1.09 | 1.09 | - | - | -10.85 | -1 | Upgrade
|
| Financing Cash Flow | -186.33 | -237.85 | -67.29 | -81.3 | 44.84 | -15.62 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.22 | 1.63 | 1.5 | 11.19 | -2.67 | -6.68 | Upgrade
|
| Net Cash Flow | 96.67 | 42.18 | -2.15 | -98.35 | -211.27 | 217.97 | Upgrade
|
| Free Cash Flow | 34.59 | 31.22 | 55.91 | -52.13 | -242.66 | 48.76 | Upgrade
|
| Free Cash Flow Growth | -29.26% | -44.16% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 3.40% | 2.90% | 4.86% | -3.81% | -17.06% | 3.17% | Upgrade
|
| Free Cash Flow Per Share | 0.10 | 0.09 | 0.16 | -0.17 | -0.68 | 0.14 | Upgrade
|
| Cash Income Tax Paid | 45.62 | 63.58 | 46.39 | -3.27 | 71.81 | 65.71 | Upgrade
|
| Levered Free Cash Flow | 34.19 | 16.38 | 206.97 | 18.73 | -210.42 | 115.99 | Upgrade
|
| Unlevered Free Cash Flow | 39.87 | 22.52 | 217.19 | 29.75 | -197.73 | 125.57 | Upgrade
|
| Change in Net Working Capital | -86.13 | -50.32 | -284.98 | -15.51 | -25.32 | -4.22 | Upgrade
|
Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.